Matthew Sause took the helm of the 4,500-person Roche Diagnostics’ North American operations in Indianapolis in November 2019—just four months before the World Health Organization declared a pandemic and much of the planet went into lockdown.
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.Read More
Elanco to cut 900 jobs in 40 countries following Bayer acquisition
The layoff is the first step in what is expected to be a major restructuring following Greenfield-based Elanco’s $6.9 billion acquisition of German conglomerate Bayer AG’s animal-health division.Read More
IU researcher’s latest biotech startup raises $34.6M
Carmel-based MBX Biosciences Inc., co-founded by serial entrepreneur Richard DiMarchi, aims to develop therapeutics to treat rare endocrine disorders.Read More
2020 Innovation Issue: Brothers share a knack for creating life sciences companies
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.Read More
This is a partial transcript of IBJ’s annual Life Sciences Power Panel, which took place virtually on April 30 with four of Indy’s biosciences leaders: 16 Tech CEO Bob Coy, GenePace Laboratories founder Sanjay Malkani, Elanco Animal Health CEO Jeff Simmons and Indiana University School of Medicine geneticist Tatiana Foroud.
Speakers at the IBJ Life Sciences Power Panel on Friday said their organizations have largely weathered the lockdown—raising records funds, taking on huge expansions, hiring new employees and reporting higher productivity.
The expansion will consist of 32 new one-bedroom apartments and five two-bedroom residences, bringing to 67 the number of assisted-living apartments at the complex.
The legislation, Senate Bill 202, would allow designated family members to visit residents under end-of-life and other serious circumstances.
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Genezen Laboratories Inc. says new funding from a Massachusetts-based private equity firm will allow it to expand its plans for a new production facility in Fishers Crosspoint Business Park.
The state’s new dashboard on COVID-19 vaccines provides interesting breakdowns on who is getting vaccinated, by county, by gender, by race, by age and a host of other statistics sure to please any proud data geek.
The 39 companies that won venture funding represent a wide range of therapeutics, devices and health information technology.
Last week, state health officials said they expected to initially receive 55,575 doses of Pfizer’s COVID-19 vaccine, and had already begun vaccinating front-line health care workers. But just five days later, state officials and hospitals are keeping mum about how many doses they actually received, except to say it was fewer than expected.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
In every significant statistical category, November has been a record-setter for the COVID-19 pandemic in Indiana, with cases, deaths and hospitalizations far exceeding even the early months of the coronavirus outbreak.
Despite the change in fortunes, Ascension signaled that it is not yet out of the woods, noting that “consumer confidence and healthcare hesitation as a result of COVID-19 continue to affect Ascension markets, to varying degrees.”
The not-for-profit launched in 2013 as a way to bridge the gap between research universities and industry in life sciences. But its report card so far is decidedly mixed, and it just hired its third CEO.
Under the Affordable Care Act, health insurers are required to spend 80% to 85% of the revenue they get from premiums on medical care. If they don’t, they have to issue rebates or credits to make up the difference.
The federal government says readmissions are often unnecessary and cost taxpayers tens of billions of dollars a year for treatments that should have been caught the first time around, or were not followed up adequately.
Indiana lags much of the nation in flu vaccination rates, and some public health officials say the combination of flu and coronavirus illness could overwhelm hospitals this winter.
State statistics reveal a very uneven, lumpy picture for COVID-19 cases from county to county, and the picture is constantly shifting.
A panel of experts spoke at IBJ’s Life Sciences Power Breakfast, which took place virtually Oct. 9, talked about venture capital in the life sciences sector. These are some excerpts.